What Biodol Therapeutics does

Biodol Therapeutics is a France-based clinical-stage biopharmaceutical company, founded in 2015 and headquartered in Montarnaud near Montpellier, developing first-in-class small-molecule FLT3 inhibitors for the treatment of chronic neuropathic pain and opioid-sparing indications. The company's core scientific thesis — validated in Nature Communications in 2018 and extended in 2024 — is that the Receptor Tyrosine Kinase FLT3 is a necessary and sufficient driver of chronic neuropathic pain, and that extracellular Negative Allosteric Modulators of FLT3 can reverse established pain (allodynia, hyperalgesia, spontaneous pain) for 48 hours after a single dose in animal models while sparing normal nervous system function. Biodol's lead asset, BDT272, entered Phase 1 clinical trials in healthy volunteers in 2025, with the broader BDT series (including BDT001) and additional oral-formulation candidates in lead optimization.

The company monetizes exclusively through pharmaceutical licensing rather than direct commercialization. Its portfolio is anchored by four granted patents, including an international composition-of-matter patent and a use patent covering any FLT3 inhibitor to treat neuropathic pain, with protection granted in both the United States and Europe. Biodol's go-to-market relies on industry partnering events (BIO, BIO-Europe, J.P. Morgan Week), academic collaborations with INSERM Montpellier and CNRS Strasbourg, and strategic licensing agreements — most notably the March 2026 license agreement with KYORIN Pharmaceutical for BDT272. Cumulative funding is approximately €11.5 million (€4.5M Series A from V-Bio Ventures in August 2020; €7M in May 2024 with Bpifrance and V-Bio Ventures), and the company employs 11-50 people.

Name

Biodol Therapeutics

Legal name

Biodol Therapeutics

Website

https://biodol.eu

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Biodol Therapeutics is a France-based clinical-stage biotech developing first-in-class small-molecule FLT3 inhibitors for chronic neuropathic pain and opioid dose-sparing applications. It monetizes through pharmaceutical licensing, with BDT272 in Phase 1 trials and a KYORIN license signed in March 2026.

Ownership category

akta.pro rank

Product category

Pain Therapeutics / Biopharmaceutical R&D

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Neuropathic pain therapeutics
• FLT3 inhibitors
• Small molecule drug discovery
• Chronic pain treatment
• Biopharmaceutical pipeline

Headquarters

HQ city

Clapiers

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing Royalties: Future revenue through licensing agreements with pharmaceutical companies for their BDT compounds and patent portfolio. License agreement signed with KYORIN Pharmaceutical in March 2026.
2. Pharmaceutical Product Sales: Revenue from commercializing first-in-class neuropathic pain treatments (BDT272 and pipeline compounds) developed for injectable or oral administration.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Biodol Therapeutics discovers and develops first-in-class small-molecule FLT3 inhibitors (BDT compounds) as Negative Allosteric Modulators for the treatment of chronic neuropathic pain and for opioid-dose sparing applications. The lead candidate BDT272 is in Phase 1 clinical trials in healthy volunteers (reported May 2025), with formulations pursued as both injectable and oral therapies. The company monetizes this pipeline through licensing agreements with pharmaceutical partners (e.g., KYORIN Pharmaceutical, March 2026) rather than direct commercialization.

Product overview

Biodol Therapeutics is a biopharmaceutical company developing a portfolio of first-in-class small-molecule FLT3 inhibitors (BDT compounds) for the treatment of chronic neuropathic pain. The core product pipeline includes BDT272 (currently in Phase 1 clinical trials), the BDT series of Negative Allosteric Modulators targeting the extracellular domain of FLT3, and BDT001 (the first discovered extracellular inhibitor). The company is developing these compounds as both injectable and oral formulations, with potential for opioid-dose sparing applications to address the Opioid Crisis. BDT compounds have demonstrated remarkable activity against neuropathic pain in animal models, with effects lasting 48 hours.

Differentiator

Problem solved

Functional benefit

Products and services

• BDT272 BDT272 is Biodol's first-in-class FLT3 inhibitor in Phase 1 clinical trials, being developed for chronic neuropathic pain as both injectable and oral therapy.
• BDT compound series (extracellular FLT3 Negative Allosteric Modulators) The BDT compound series are first-in-class small-molecule FLT3 inhibitors acting at the extracellular domain of FLT3 as Negative Allosteric Modulators, targeting chronic neuropathic pain and offering opioid-dose sparing applications.
• BDT001 BDT001 is the original extracellular inhibitor of FLT3 identified through virtual screening, demonstrated to reverse neuropathic pain symptoms in animal models and protected by patent.

Quantifiable outcome

• Single administration completely reverses established neuropathic pain symptoms including hyperalgesia, allodynia and spontaneous signs of pain
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• KYORIN PharmaceuticalflagshipOEM/ Whitelabel/ Licensing Partner · 31 March 2026License agreement signed for novel neuropathic pain treatment. KYORIN Pharmaceutical obtained rights to develop and commercialize BDT272 for neuropathic pain treatment. Prior option agreement was announced in January 2025.
• INSERM Institute for Neurosciences of MontpelliercoreStrategic or Co-development PartnerAcademic partnership with Cyril Rivat and Jean Valmier for discovery of FLT3 role in chronic pain. Jean Valmier serves as Principal Scientific Advisor and leads the laboratory at INSERM Institute for Neurosciences of Montpellier (INM).
• Laboratory for Therapeutic Innovation (LIT) - CNRS/Université de StrasbourgcoreStrategic or Co-development PartnerAcademic research partnership with Didier Rognan as Research Director at CNRS and Director of LIT. Didier Rognan is a worldwide recognized specialist of virtual screening and contributed to development of BDT compounds through virtual screening.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vertex Pharmaceuticals: Vertex Pharmaceuticals received FDA approval for Journavx (suzetrigine), a first-in-class selective NaV1.8 inhibitor for acute pain in 2025, with ongoing development in neuropathic pain. As a developer of first-in-class small-molecule pain therapeutics with strong clinical and commercial capabilities, Vertex is the most directly comparable peer to Biodol's BDT272 program.

Broad incumbents

• Grünenthal: Grünenthal is a German privately-held pharmaceutical company specializing in pain therapeutics, with a portfolio including established products in neuropathic pain (e.g., Versatis/lidocaine patch, Qutenza/capsaicin) and active development of novel pain mechanisms. Comparable as a focused pain franchise player where Biodol's pipeline could fit as a licensing partner or acquirer.
• Lexicon Pharmaceuticals: Lexicon Pharmaceuticals has historically developed pain therapeutics including those targeting novel mechanisms in neuropathic pain. Comparable as a mid-cap biopharmaceutical company with clinical-stage pain pipeline assets and partnership-oriented business model.
• AbbVie: AbbVie markets major neuropathic pain treatments (e.g., Botox for chronic migraine, established CNS franchise) and is a frequent partner/licensee for mid-stage pain biotechs. Comparable as a large incumbent with established commercial channels in neuropathic pain that Biodol could partner with for ex-Japan rights.
• Pfizer: Pfizer markets Lyrica (pregabalin), one of the leading approved treatments for neuropathic pain, and has active interest in novel pain mechanisms. Comparable as a broad incumbent with major neuropathic pain franchise and a logical potential licensor for Biodol's BDT272 outside Asia.

Emerging players

• Eliem Therapeutics: Eliem Therapeutics is a clinical-stage biotechnology company developing novel treatments for hyperexcitability disorders of the central nervous system, including neuropathic pain. Comparable as an emerging biotech with similar size, clinical-stage CNS/pain pipeline, and licensing-oriented business model to Biodol.
• Latigo Biotherapeutics: Latigo Biotherapeutics is a clinical-stage biotech developing non-opioid pain therapeutics targeting Nav1.7 and Nav1.8 sodium channels. Comparable as an emerging pain-focused biotech pursuing novel small-molecule mechanisms in neuropathic pain, with similar clinical-stage development profile to Biodol's BDT272.
• Hoba Therapeutics: Hoba Therapeutics is a Danish biotech developing novel therapeutics for chronic neuropathic pain, including biologics targeting specific pain pathways. Comparable as a small emerging European biotech focused exclusively on neuropathic pain indications with novel mechanism approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biodol Therapeutics